Abstract:Background: Molecular stratification and tailored target therapy bring clinical benefit for patients with triple-negative breast cancer (TNBC), but it is difficult to implement comprehensive molecular testing in clinical practice. Thus, we aim to devise an approach based on digital pathology and deep learning for the molecular and prognostic stratification of TNBC.Methods: We collected digital whole slide images (WSIs) (N=425) of our previously established TNBC cohort with multi-omics data. A deep learning-based workflow was developed and applied to these WSIs to train and validate neural network models to predict multi-omics molecular features, to identify molecular subtypes, and to improve prognostic evaluation. The models that showed high prediction accuracy were further validated on the TNBC cases from TCGA (N=143).Findings: A model was first developed for automatic tissue type classification, which enabled selection of certain tissue types on WSIs for the following prediction. Numerous molecular features can be inferred from WSIs including the somatic PIK3CA mutation, germline BRCA2 mutation and PD-L1 expression. All of the four molecular subtypes of TNBC can be accurately identified based on WSIs and distinctive morphological patterns were revealed for each subtype. The addition of image features to clinical prognostic factors significantly improved the accuracy of relapse risk assessment. The models for predicting PIK3CA mutation, PD-L1 expression, TNBC subtypes and relapse risk can be well generalized to the TCGA TNBC cases. The complete prediction workflow along with validated models was modularized and deployed on an online platform, which can realize real-time one-stop prediction for newly-uploaded WSIs.Interpretation: We proposed a deep learning-based workflow and developed neural network models to predict clinically relevant information of TNBC from pathological WSIs. Our findings and established platform may enable the implementation of artificial intelligence guided precision treatment in clinical trials and future routine practice.Funding: Fudan University Shanghai Cancer Center.Declaration of Interest: None to declare Ethical Approval: The tissue samples used in our study were obtained after the approval from the FUSCC Ethics Committee.

A novel computer-assisted tool for 3D imaging of programmed death-ligand 1 expression in immunofluorescence-stained and optically cleared breast cancer specimens

Computer-assisted three-dimensional quantitation of programmed death-ligand 1 in non-small cell lung cancer using tissue clearing technology

Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue

In Vivo Characterization of PD-L1 Expression in Breast Cancer by Immuno-Pet With

Deep Learning and Digital Pathology Power Precision Treatment of Triple-Negative Breast Cancer

NIR-II Fluorescent Molecular Bottlebrush Prepared by Ring-Opening Polymerization for Programmed Cell Death Ligand-1 Checkpoint Imaging

Improved Resection and Prolonged Overall Survival with PD-1-IRDye800CW Fluorescence Probe-Guided Surgery and PD-1 Adjuvant Immunotherapy in 4T1 Mouse Model

Assembly of Nanocatalyst As a Noninvasive Tool for Breast Cancer Diagnosis and Immunotherapy Surveillance Designed by Visually Tracking Tumor-Derived Exosomal PD-L1

Artificial intelligence-assisted system for precision diagnosis of PD-L1 expression in non-small cell lung cancer

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer

A Pipeline for Evaluation of Machine Learning/Artificial Intelligence Models to Quantify Programmed Death Ligand 1 Immunohistochemistry

Bio-orthogonal click chemistry strategy for PD-L1-targeted imaging and pyroptosis-mediated chemo-immunotherapy of triple-negative breast cancer

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Optimization of Cancer Immunotherapy on the Basis of Programmed Death Ligand‐1 Distribution and Function

AUNP-12 Near-Infrared Fluorescence Probes across NIR-I to NIR-II Enable In Vivo Detection of PD-1/PD-L1 Axis in the Tumor Microenvironment

Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1–positive Triple-negative Breast Cancer

Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1

Artificial intelligence enhances whole‐slide interpretation of PD‐L1 CPS in triple‐negative breast cancer: A multi‐institutional ring study

Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer

Multifunctional Probe Based on "Chemical Antibody-Aptamer" for Noninvasive Detection of PD-L1 Expression in Cancer